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Although advanced ovarian carcinoma (FIGO stages III–IV) is
sensitive to chemotherapy, with response rates of 70–80% follow-
ing treatment with platinum/taxane combinations in ﬁrst line
regimens, the majority of patients relapse and their management
at this stage is often unclear. A plethora of cytotoxic agents have
been shown to have activity in this group in the last decade. In
patients relapsing within 12 months of ﬁrst-line chemotherapy,
response rates to these agents however, are in the order of 20%
with progression free intervals of 5–9 months only (Gore, 2001).
The most important predictive factor for response to
chemotherapy is the progression-free interval, a phenomenon ﬁrst
described by Blackledge et al (1989). The response to phase II
agents was correlated with time since last treatment. Patients whose
disease progressed less than 6 months from their last chemotherapy
had a response rate of less than 10% whilst those more than 18
months from treatment had a 94% chance of responding. Subse-
quent work (Markman et al, 1991), conﬁrmed that this is a
general predictor of chemosensitivity and that response to rechal-
lenge with a platinum-based therapy is highly dependent on
treatment-free interval with only 27% of patients 5–12 months
from completion of cisplatin therapy responding compared with
59% of those whose disease progressed more than 24 months after
initial treatment.
At present, current practice is to rechallenge patients relapsing
more than 6–12 months after ﬁrst-line chemotherapy with plati-
num-based regimens and to consider those relapsing sooner or
who have truly refractory disease for newer agents, preferably with-
in a clinical trial.
WEEKLY CISPLATIN AND ORAL ETOPOSIDE
The article presented by Van der Burg et al (2002) in this issue,
may come to challenge this view. The authors report impressive
response rates and progression free survival in platinum-sensitive,
resistant and refractory disease when treated with weekly cisplatin
and prolonged daily oral etoposide. One hundred and seven
patients were treated with an induction therapy of cisplatin 50 or
70 mg m
72 dissolved in 3% sodium chloride on days 1, 8, 15,
29, 36 and 43 together with oral etoposide 50 mg daily on days
1–15 and 29–43. Patients whose disease remained stable or
responded continued on oral etoposide for a planned further 6–
9 cycles at the same dose for 21 consecutive days in 28. All patients
had bidimensionally measurable disease on cross-sectional imaging.
However only the 98 patients completing induction therapy were
evaluated for response rather than an intention-to-treat analysis
being performed.
Of the 38 patients with platinum-sensitive disease, 92%
responded to therapy with a median survival of 26 months,
91% of the patients with platinum-intermediate disease (a plati-
num free interval of 4–12 months) responded with a median
survival of 16 months. Importantly 46% of 28 patients with
platinum-refractory disease (platinum free interval of less than
4 months) responded although the median duration of this
was only 5 months with median survival being 13 months.
Myelotoxicity during cisplatin administration was cumulative
with grade III/IV leucopenia seen in 58% of patients receiving
70 mg m
72 and grade III/IV thrombocytopenia in 40%.
However, only one case of neutropenic fever was documented
and only 10% of patients needed more than a 1 week delay
in treatment. Reported non-haematological toxicity was in gener-
al mild with nephrotoxicity limited to grade I/II in 4% of
patients whilst grade II sensory neuropathy was only seen in
7%. Prolongation of etoposide monotherapy was associated with
grade IV neutropenia in only 2% of cycles.
PREVIOUS STUDIES
Several previous studies have demonstrated response rates of 0–
27% in patients with platinum-resistant disease that were treated
with oral etoposide monotherapy (Markman et al, 1992; Marzola
et al, 1993; De Wit et al, 1994; Hoskins and Swenerton, 1994;
Seymour et al, 1994; Kavanagh et al, 1995; Kuhn et al, 1996; Rose
et al, 1998). The largest reported a response rate of 27% in 41
patients who had recurrent disease within 6 months of completing
platinum-based chemotherapy although median survival was only
10.8 months (Rose et al, 1998).
Previous data for weekly cisplatin salvage therapy is sparse. Two
early phase II studies showed response rates of 62.5 and 70% in
eight and 10 patients respectively for its use as third line therapy
(Piver et al, 1980; Scotto and Sbiroli, 1991). One larger study of
72 patients whose disease had previously responded to cisplatin
reported an overall response rate of 70% to weekly cisplatin at
1m gk g
71 for 9 weeks in combination with either intravenous
etoposide, epirubicin or carboplatin. Of note, 20 of 33 patients
whose disease had relapsed within 18 months of initial diagnosis
responded (Bolis et al, 1994). Evidence for the use of dose-dense
cisplatin as ﬁrst-line chemotherapy is disappointing. Whilst Levin
et al (1993) in their meta-analysis of dose intensity in ovarian
cancer chemotherapy demonstrated a statistically signiﬁcant corre-
lation between response rate and cisplatin dose intensity, the Received 6 November 2001; accepted 13 November 2001
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large studies comparing nine doses of weekly cisplatin
50 mg m
72 to either conventional 3-weekly cisplatin at 75 mg
m
72 (Colombo et al, 1993) or combination cisplatin and cyclo-
phosphamide (Bolis et al, 1997) showed equivalence only. One
study of 101 patients however revealed a trend towards increased
survival at 5 years in favour of weekly compared to 3-weekly cispla-
tin (Cocconi et al, 1999).
Importantly, Meyer et al (2001) present a retrospective analysis
of 42 patients with relapsed ovarian cancer treated with a similar
weekly regimen. Cisplatin (60 mg m
72) was administered on days
1, 8, 15, 29, 36 and 43 and 50 mg oral etoposide was given on days
1–14 and 29–43 although this was only continued for a maxi-
mum of two cycles after induction therapy in patients whose
disease responded. Response rate was assessed by CA-125 criteria
only and 46% of patients whose disease had relapsed within 6
months of platinum-based chemotherapy responded to this weekly
regimen. However, only 43% of patients with a platinum-free
interval of more than 6 months responded. The median survival
was 6.3 and 6.9 months respectively in these groups and the toxi-
city was similar to that reported by Van der Burg et al (2002).
Whilst both Van der Burg et al (2002) and Meyer et al (2001)
report impressive response rates in platinum resistant disease with
weekly cisplatin and prolonged oral etoposide, how do we explain
the large discrepancies in overall survival and response rates in
platinum-sensitive patients in these studies? As well as the deﬁni-
tions of platinum-sensitive disease being different (platinum-free
intervals of 12 and 6 months respectively), in the study by Meyer
et al (2001) platinum-sensitive patients had received more prior
chemotherapy (2.63 courses compared to 1.13) and had a shorter
platinum free interval (10.5 months vs 25 months). Their patients
were also treated outside of a clinical trial and so may be more
representative of the diverse spectrum of patients seen in general
clinical practice – however Meyer et al (2001) do not comment
on tumour bulk or performance status which are prognostic factors
that may also explain this ﬁnding (Eisenhauer et al, 1997; Gore,
2001).
WEEKLY CHEMOTHERAPY: TOXICITY AND EFFICACY
Whilst the combination of the two approaches presented here
demonstrates markedly better response rates than that seen with
monotherapy in relapsed ovarian cancer, it is different from other
combination treatments in that toxicity appears to be less marked.
For instance, the combination of mitoxantrone and paclitaxel has
been recently reported to have a response rate of 69% in a predo-
minantly platinum-refractory population of 33 patients. Grade III/
IV neutropenia was however seen in 64% of cycles (compared with
16% of cisplatin doses as reported by Van der Burg et al (2002))
and G-CSF support was required in 49% (Janat et al, 2000).
As our principal aim in treating relapsed ovarian cancer is
palliative, careful attention should therefore be paid to toxicity
when designing combination strategies. Administering chemother-
apy weekly to modify the side-effect proﬁle without decreasing
efﬁcacy is a well-established policy in other solid malignancies. In
breast cancer, the administration of taxanes weekly in metastatic
disease decreases markedly the incidence of signiﬁcant myelosup-
pression and grade III/IV toxicities overall (Perez et al, 1999;
Burstein et al, 2000). This approach has also been adopted in
relapsed advanced ovarian cancer with 3-weekly (200 mg m
72)
and weekly paclitaxel (67 mg m
72) being demonstrated to be
equally efﬁcacious in paclitaxel-naı ¨ve patients with markedly fewer
toxicities apart from nail changes and lethargy in the weekly arm
(Andersson et al, 2000). There is also preliminary evidence from
two studies to suggest that patients refractory to both platinum
and 3-weekly paclitaxel may respond to weekly administration
(Belinson et al, 2000; Kaern et al, 2001). Whether this is due to
more prolonged cancer cell exposure to the taxane or the emer-
gence of other mechanisms of action such as an anti-angiogenic
effect is unclear.
One concern persists with the use of prolonged oral etoposide,
in particular in combination with a platinum. It is well established
that topoisomerase II inhibitors are leukaemogenic by increasing
the risk of balanced chromosomal translocations. Etoposide is clas-
sically associated with de novo onset acute myeloid leukaemia
characterized by a rearrangement involving the MLL gene on Chro-
mosome 11q23 that has a latency of 2–3 years (Felix and
Megonigal, 2001). Whilst only one case was reported in the
GOG study discussed above (Rose et al, 1998) and none in this,
it has been estimated that the cumulative risk with prolonged oral
exposure may be as high as 4% (Pui and Relling, 2000). Although
this consideration may not be prominent in the treatment of recur-
rent ovarian cancer attempts to evaluate this regimen in the ﬁrst
line treatment of the disease would be limited by concern over long
term myelotoxicity and therefore the evaluation of weekly cisplatin
with, for example, a taxane would be of great interest. Notably, two
preliminary reports have already demonstrated the feasibility and
promise of this approach in both platinum-sensitive and -resistant
disease with acceptable toxicity (Bolanos et al, 2001; Katsumata et
al, 2001).
CONCLUSIONS AND FUTURE STUDIES
Two studies have reported striking response rates in women with
platinum-refractory disease who were treated with weekly cisplatin
and etoposide. Van der Burg et al (2002) suggest that all patients
with recurrent disease should therefore be considered for rechal-
lenge with weekly cisplatin. To what extent do their data support
this thesis? The correlation between response to chemotherapy
and patient survival is variable and with regard to weekly cisplatin
and etoposide this will only be unravelled in the context of a
randomized phase III trial. Such a study should also take the
opportunity to collate detailed quality of life data given that recur-
rent ovarian cancer is generally incurable. It will also evaluate the
importance of prior taxane exposure, an issue not addressed in this
study as these agents only entered routine ﬁrst line use in the last 5
years.
If the response rates shown in this study are conﬁrmed, it will be
important to re-evaluate the use of chemotherapy in relapsed ovar-
ian cancer associated with bowel obstruction. This is a common
and difﬁcult problem and its course proves extremely distressing
to both patients and their family. Previous studies have failed to
show a beneﬁt with chemotherapy but the development of a regi-
men with a high response rate, in particular if this is associated
with a short time to response, would be a vital addition to our
current management strategy.
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